metabolites in human. In the course of clinical study for the coadministration ofPIPC with a /Mactamase inhibitor, tazobactam3), an active metabolite ofPIPC (1) which is distinct from T-1220A was found in human plasma and urine. The metabolite 1 was also found in the same manneron the administration of PIPCalone, suggesting that the metabolism of PIPC was not affected by the co-administration o...

Title: In vitro antibacterial activity of piperacillin versus piperacillintazobactam on gram negative clinical isolates from a tertiary care hospital.Objective :To compare in-vitro antibacterial activity of piperacillin with piperacillin-tazobactam combination on the most common isolates of gram negative bacilli obtained from various clinical samples from a tertiary care hospital. Methodology :...

tazobactam. The addition of tazobactam was of no benefit in strains producing GES, VEB and PER b-lactamases, which all had CXA-101 MICs .64 mg/L. In the only isolate producing an ESBLM-D b-lactamase (OXA-32), the MIC was reduced from .64 to 8 mg/L. The OXA-32-producing isolate was also susceptible to piperacillin/tazobactam. Susceptibility to piperacillin/ tazobactam was additionally seen in on...

Of 41 patients with bone-related infections who were treated for > or =10 days with piperacillin-tazobactam, 14 (34%) developed neutropenia. Cumulative doses of piperacillin administered to neutropenic patients were higher than those administered to nonneutropenic ones (330 vs. 237 g; P=.008), and an inverse correlation was detected between the absolute neutrophil count at the end of treatment ...

BACKGROUND extended spectrum β-lactamase (ESBL) producing gram negative bacilli are becoming a growing problem worldwide with difficulties in designing a national formulary for empirical treatment of gram negative sepsis. OBJECTIVES In this study, we investigated the in vitro activity of Carbapenems, Pipracillin-Tazobactam, Ciprofloxacin alone or in combination with aminoglycosides against ES...

OBJECTIVES Appropriate antibiotic exposure at the site of infection is important for clinically effective therapy. This study compared the epithelial lining fluid (ELF) penetration of ceftolozane/tazobactam, which has potent in vitro activity against many Gram-negative pathogens causing nosocomial pneumonia, with that of piperacillin/tazobactam in healthy adult volunteers. METHODS In this Pha...

A 20-year-old nonverbal patient with profound developmental disabilities was treated with intravenous piperacillin-tazobactam for respiratory infection. After 8 days, he became afebrile with normal pulmonary status, but his pulse remained inexplicably rapid (114/minute). Investigations revealed severe normochromic normocytic hemolytic anemia (hemoglobin: 40 g/L, reticulocytes: 9.4%, nucleated e...

The possible reactivities of commonly used antibiotics of fungal, nonfungal, and nonmicrobial or synthetic sources with the Platelia Aspergillus galactomannan assay were assessed. For drugs that tested positive, the minimal concentration of the antibiotic in serum that yielded a positive test (index, >0.5) was determined. At undiluted concentrations, piperacillin and multiple lots of piperacill...

A study of antimicrobial agents sensitivity using the microdilution system incorporated to identification/susceptibility of non-fermenting gram-negative of Microscan panels, was made, taking into account the breakpoints in the Clinical and Laboratory Standards Institute (CLSI). Studied strain was sensitive to most of the antibiotics tested as: cefotaxime, cefepime and piperacillin/tazobactam, g...

ACHN-490 was tested alone and in combination with cefepime, doripenem, imipenem, or piperacillin-tazobactam in a synergy time-kill analysis against 25 Pseudomonas aeruginosa strains with different resistance phenotypes. Each combination was synergistic against most isolates at 24 h, and antagonism was not observed. Combinations of ACHN-490 with cefepime, doripenem, imipenem, or piperacillin-taz...